Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Takeda Pharma's India operations become United Nations Global Compact signatory

Ruchika Sharma27 Sept 2022 1:15 PM IST

New Delhi: Takeda Pharmaceutical Company Limited has announced that its India operations have become a signatory of the United Nations Global Compact...

Biocon Founder Kiran Mazumdar-Shaw conferred with HK Firodia Lifetime Achievement Award 2022

Ruchika Sharma27 Sept 2022 12:13 PM IST

The awards are given to eminent Indian scientists for their original and world-class contributions to any branch of science or technology.

Pfizer, BioNTech seek USFDA emergency use nod for Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster for Children aged 5 through 11 years

Ruchika Sharma27 Sept 2022 11:15 AM IST

COMIRNATY (COVID-19 Vaccine, mRNA) is a vaccine approved for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute...

PAG-led API Platform concludes acquisition of controlling stake in Optimus Group

Ruchika Sharma26 Sept 2022 4:30 PM IST

The deal follows the acquisition of Anjan Drugs in 2020 by the consortium, which aims to develop a best-in-class center for the development and...

Allergan MD Suresh Pattathil elected as new President of OPPI

Ruchika Sharma26 Sept 2022 3:00 PM IST

Mumbai: The Organisation of Pharmaceutical Producers of India (OPPI), which represents the research-based pharmaceutical companies, has elected Suresh...

Mizoram: Contraband drugs worth more than Rs 84 crore seized in Champhai district

Ruchika Sharma26 Sept 2022 2:30 PM IST

Champhai: Police recovered and seized a large quantity of contraband drugs worth more than Rs 84 crore in Mizoram's Champhai district, said Mizoram...

CEO of Pfizer tests COVID positive again

Ruchika Sharma26 Sept 2022 1:45 PM IST

The chief executive said he has not yet taken the new bivalent booster.

Natco Pharma unveils Chlorantraniliprole (CTPR) formulated product NATGEN in India

Ruchika Sharma26 Sept 2022 12:40 PM IST

Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced that the company has launched Chlorantraniliprole (CTPR) 18.5% SC under the Brand...

Bharat Biotech Chief says PLI schemes should also focus on entities supporting production of branded pharma products

Ruchika Sharma26 Sept 2022 11:15 AM IST

"Lots of consumer durables, raw materials and packing materials were in short supply because we are not making them here in the country. It is very...

Novartis intrathecal onasemnogene abeparvovec Phase III study

Novartis to prioritise US market, unfazed by drug pricing pushback

Ruchika Sharma25 Sept 2022 2:51 PM IST

Novartis aspire to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.

GSK Nucala application for COPD accepted for review in China

GSK, Spero Therapeutics ink pact for complicated urinary tract infections antibiotic Tebipenem pivoxil hydrobromide

Ruchika Sharma25 Sept 2022 1:13 PM IST

GSK will receive an exclusive licence to develop and commercialise tebipenem pivoxil HBr in all countries except Japan and certain other Asian...

AstraZeneca discontinues Phase 3 trial of prostate cancer drug Truqap

AstraZeneca Ultomiris approved in Europe for treatment of adults with generalised myasthenia gravis

Ruchika Sharma25 Sept 2022 12:00 PM IST

Ultomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete and sustained complement inhibition.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok